Cancer is one of the leading causes of death in dogs, particularly in middle-aged to older animals. Navigating cancer diagnosis and treatment decisions requires balancing welfare considerations, owner values, and realistic outcome expectations in a compassionate, evidence-based way.
Approximately 1 in 4 dogs will develop cancer during their lifetime, rising to nearly 50% of dogs over 10 years old. Common canine cancers include: mast cell tumours (most common skin tumour), lymphoma (affecting lymph nodes, spleen, liver), osteosarcoma (bone cancer, common in large breeds), haemangiosarcoma (vascular tumour — spleen and heart), mammary tumours (in non-spayed females), and transitional cell carcinoma (bladder). Breed predispositions are significant — Golden Retrievers, Boxers, and Bernese Mountain Dogs have notably high cancer rates.
Early cancer detection improves welfare by enabling treatment before disease is advanced. Warning signs include: unexplained lumps or bumps (any new growth warrants veterinary assessment), unexplained weight loss, reduced appetite, lethargy, difficulty breathing or swallowing, persistent lameness, abnormal bleeding or discharge, and abdominal distension. Regular veterinary health checks, particularly in senior dogs, enable detection of early-stage cancers.
Treatment decisions for canine cancer must centre on quality of life, not just survival extension. Questions to consider: What are the realistic outcomes (cure vs. remission vs. palliation)? What are the treatment side effects and how will the dog experience them? Can the dog's quality of life be maintained during treatment? What is the owner's ability and willingness to manage treatment-related complications? Honest veterinary communication about prognosis and treatment burden is essential for welfare-centred decision-making.
Treatment modalities and their welfare considerations: Surgery—often the most effective treatment for localised solid tumours; provides rapid relief of tumour-related symptoms; post-operative pain management is essential. Chemotherapy—generally better tolerated by dogs than humans (lower doses used); nausea, neutropenia, and reduced activity are common side effects; most dogs maintain quality of life during treatment. Radiation therapy—effective for some tumours; requires multiple anaesthetic sessions; acute radiation effects (skin changes, mucositis) require management. Palliative care—pain management, appetite support, and comfort without curative intent; appropriate when cure is not possible or treatment burden outweighs benefit.
Cancer pain requires proactive, multimodal management. NSAIDs, opioids (tramadol, buprenorphine), gabapentin, and amantadine are used in combination to manage different pain pathways. Regular pain assessment using validated tools enables appropriate dose titration. Palliative radiotherapy reduces bone pain from osteosarcoma significantly. Nutritional support maintains condition and wellbeing during treatment.
Validated quality of life scales (HHHHHMM scale — Hurt, Hunger, Hydration, Hygiene, Happiness, Mobility, More good days than bad) provide structured frameworks for ongoing welfare assessment. Regular assessment helps owners recognise when quality of life has declined below an acceptable threshold. Euthanasia at an appropriate time — before severe suffering — is a compassionate welfare option that veterinarians should discuss proactively rather than reactively.